Evidence map›Paper›PMID 35425727›Full record

ArticleFrontiers in pediatrics2022

Efficacy of Phenotype-vs. Genotype-Guided Therapy Based on Clarithromycin Resistance for

Yan Feng, Wenhui Hu, Yuhuan Wang, Junping Lu, Ye Zhang, Zifei Tang, Shijian Miao, Ying Zhou, Ying Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025
    Review
  2. Opportunities forMicroorganisms · 2024
    Review
  3. Antibiotics (Basel, Switzerland) · 2023
    Review
  4. Current Worldwide Trends in PediatricChildren (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan FengDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Wenhui HuDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Yuhuan WangDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Junping LuDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Ye ZhangDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Zifei TangDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Shijian MiaoDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Ying ZhouDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.
Ying HuangDepartment of Gastroenterology, Children's Hospital of Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clarithromycin resistance reduces the eradication rate of Methods: We retrospectively enrolled patients aged 6 and 18 years with Results: Between September 2017 and October 2020, 226 eligible patients were enrolled. There were 71 with clarithromycin-sensitive strains in the phenotype-guided therapy group and 87 without 23S rRNA point mutations (A2142G, A2142C, and A2143G) in the genotype-guided therapy group. Eradication rates were 70.4% (50/71, [95% CI: 58.4-80.7%] for phenotype-guided therapy and 92.0% (80/87, [95% CI: 84.1-96.7%]) for genotype-guided therapy ( Conclusion: Tailored therapy according to genetic testing results achieved eradication rates of 92% and was superior to tailored therapy guided by traditional culture results.

Indexed as

clarithromycin resistancegenotypeHelicobacter pyloriphenotypetailored therapy

Identifiers

PMID35425727
PMCPMC9002118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.